By Adriano Marchese
McKesson has agreed to acquire a controlling interest in eye-health company PRISM Vision Holdings for $850 million as it looks to develop a retinal and ophthalmology platform.
The diversified healthcare services company said Tuesday it will acquire an 80% stake in the company, while PRISM Vision physicians will continue to retain a 20% interest in the business.
McKesson chief executive, Brian Tyler, said the acquisition strengthens its community practice and specialty solutions, while building a platform to serve a high-growth area of retina and ophthalmology.
"We intend to develop a leading platform for retinal care, delivering differentiated solutions and value across providers, biopharma partners and patients," Tyler said.
McKesson expects PRISM Vision to add about 20 cents to 30 cents to its adjusted earnings per share in the first 12 months following the close of the transaction, and then to be between 65 cents and 75 cents accretive by the end of the third year.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
February 04, 2025 08:30 ET (13:30 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.